

Technology Advisory Interests Register

Topic: Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	TAC Committee Member	Financial	I am currently working with Pfizer and Gilead in unrelated indications (NSCLC and Gastric Cancer). In the last 12 months I have worked with JNJ for multiple myeloma.	16/10/2025 05/02/2026	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Mike Chambers	TAC Committee Member	Financial	I have participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: prostate cancer	16/10/2025	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Jonathan Sive	TAC Committee Member	Financial	I was sponsored to attend a medical conference by Johnson & Johnson (Janssen-Cilag)	17/10/2025 06/02/2026	It was agreed that Jonathan's declaration would not prevent them from participating in discussions on this appraisal
Kate Ren	TAC Committee Member	Financial	I provided consultancy services to a potential comparator company, BeOne, for zanubrutinib in chronic lymphocytic leukaemia.	09/02/2026	It was agreed that Kate's declaration would prevent them from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			I also provided consultancy service to a possible comparator company, Pfizer, for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).		discussions on this appraisal
Dr Renata Walewska	Expert	Direct - Financial	<ul style="list-style-type: none"> • Speaker engagements: AbbVie, AstraZeneca, BeOne Medicines Ltd, Eli Lilly, Janssen • Advisory boards: AbbVie, AstraZeneca, BeOne Medicines Ltd, Janssen, Eli Lilly, SecuraBio • Meeting sponsorship: AbbVie, AstraZeneca, BeOne Medicines Ltd, Janssen, Takeda • Educational material development: BeOne Medicines Ltd, Limbic, Medscape 	22/07/2025, 10/11/2025	It was agreed that Renata's declaration would not prevent them from providing expert advice to the committee